{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:09:54Z","timestamp":1793088594397,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Medical Scientific Research Fund","award":["FRSM-IREC88A6"],"award-info":[{"award-number":["FRSM-IREC88A6"]}]},{"name":"Osteogenesis Imperfecta"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bone.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:24:48Z","timestamp":1556627088000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta"],"prefix":"10.1016","volume":"124","author":[{"given":"Micka\u00ebl","family":"Cardinal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Tys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-9513","authenticated-orcid":false,"given":"Daniel","family":"Chappard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-329X","authenticated-orcid":false,"given":"Guillaume","family":"Mabilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nyssen-Behets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Manicourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/ajmg.a.35327","article-title":"Analysis of skeletal dysplasias in the Utah population","volume":"158A","author":"Stevenson","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"issue":"9","key":"10.1016\/j.bone.2019.04.011_bb0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9418","key":"10.1016\/j.bone.2019.04.011_bb0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0020","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2019.04.011_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch. Osteoporos."},{"issue":"9","key":"10.1016\/j.bone.2019.04.011_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.1942","article-title":"Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1","volume":"28","author":"Ben Amor","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"26","key":"10.1016\/j.bone.2019.04.011_bb0035","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause","volume":"310","author":"Paterson","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0040","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jbmr.2172","article-title":"How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone","volume":"29","author":"Carriero","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.04.011_bb0045","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0050","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1542\/peds.99.2.e3","article-title":"Osteogenesis imperfecta in childhood: impairment and disability","volume":"99","author":"Engelbert","year":"1997","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0055","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.apmr.2003.08.085","article-title":"Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up","volume":"85","author":"Engelbert","year":"2004","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0003-9993(98)90207-6","article-title":"Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta","volume":"79","author":"Gerber","year":"1998","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1302\/0301-620X.80B6.0800999","article-title":"Surgical stabilisation of the lower limb in osteogenesis imperfecta using the Sheffield telescopic intramedullary rod system","volume":"80","author":"Wilkinson","year":"1998","journal-title":"J. Bone Joint Surg. Br."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1302\/0301-620X.93B5.25499","article-title":"Fracture in long bones stabilised by telescopic intramedullary rods in patients with osteogenesis imperfecta","volume":"93","author":"Cho","year":"2011","journal-title":"J. Bone Joint Surg. Br."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","article-title":"Clinical review 1: bisphosphonate use in childhood osteoporosis","volume":"94","author":"Bachrach","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","article-title":"Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review","volume":"51","author":"Castillo","year":"2009","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MED.0000000000000367","article-title":"Osteogenesis imperfecta: diagnosis and treatment","volume":"24","author":"Palomo","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bone.2019.04.011_bb0105","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.04.011_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00024677-200605040-00004","article-title":"Osteogenesis imperfecta: current treatment options and future prospects","volume":"5","author":"Devogelaer","year":"2006","journal-title":"Treat. Endocrinol."},{"issue":"10","key":"10.1016\/j.bone.2019.04.011_bb0115","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1359\/jbmr.1999.14.2.264","article-title":"The material basis for reduced mechanical properties in oim mice bones","volume":"14","author":"Camacho","year":"1999","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S8756-3282(02)00974-2","article-title":"Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta","volume":"32","author":"Evans","year":"2003","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0135","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI33612","article-title":"Building bone to reverse osteoporosis and repair fractures","volume":"118","author":"Khosla","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2019.04.011_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fmats.2017.00027","article-title":"Sost deficiency does not alter bone's lacunar or vascular porosity in mice","volume":"4","author":"Mosey","year":"2017","journal-title":"Front. Mater."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2019.04.011_bb0165","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.04.011_bb0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0175","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.011_bb0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2019.04.011_bb0185","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"9902","key":"10.1016\/j.bone.2019.04.011_bb0190","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(13)61531-7","article-title":"Oral bisphosphonates for paediatric osteogenesis imperfecta?","volume":"382","author":"Ward","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0195","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bone.2019.04.011_bb0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bone.2007.12.215","article-title":"Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim)","volume":"42","author":"Carleton","year":"2008","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(96)00305-5","article-title":"Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta","volume":"19","author":"Saban","year":"1996","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2019.04.011_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1258\/la.2010.009085","article-title":"Isoflurane and sevoflurane provide equally effective anaesthesia in laboratory mice","volume":"44","author":"Cesarovic","year":"2010","journal-title":"Lab. Anim."},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bone.2012.05.001","article-title":"Effects of ovariectomy on the changes in microarchitecture and material level properties in response to hind leg disuse in female rats","volume":"51","author":"Maimoun","year":"2012","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0220","first-page":"43","article-title":"Essential amino acid supplements increase muscle weight, bone mass and bone strength in adult osteoporotic rats","volume":"1","author":"Ammann","year":"2000","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"9","key":"10.1016\/j.bone.2019.04.011_bb0225","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1359\/jbmr.070607","article-title":"Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength","volume":"22","author":"Ammann","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2019.04.011_bb0230","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1600-0501.2008.01553.x","article-title":"Orthodontic loading of titanium miniplates in dogs: microradiographic and histological evaluation","volume":"19","author":"Cornelis","year":"2008","journal-title":"Clin. Oral Implants Res."},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0240","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry nomenclature committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0245","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10439-013-0793-7","article-title":"Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model","volume":"41","author":"Yao","year":"2013","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.bone.2019.04.011_bb0250","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1196\/annals.1402.014","article-title":"Regulation of skeletal remodeling by the endocannabinoid system","volume":"1116","author":"Bab","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bone.2019.04.011_bb0255","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0265","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0270","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0275","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Li","year":"2018","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bone.2019.04.011_bb0280","first-page":"367","article-title":"Current and emerging treatments for the management of osteogenesis imperfecta","volume":"6","author":"Monti","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"issue":"19","key":"10.1016\/j.bone.2019.04.011_bb0285","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2019.04.011_bb0290","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2019.04.011_bb0295","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0300","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2131\/jts.37.617","article-title":"Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))","volume":"37","author":"Watanabe","year":"2012","journal-title":"J. Toxicol. Sci."},{"issue":"16","key":"10.1016\/j.bone.2019.04.011_bb0305","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0310","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2019.04.011_bb0315","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0320","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.011_bb0325","series-title":"Oral Presentation of Selected Posters at: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 2015 Mars 26\u201329; Milan, Italy; Presentation Number: 642","article-title":"Sclerostin antibody improves vertebrae parameters in murine model of severe osteogenesis imperfecta, WCO-IOF-ESCEO 26 Suppl 1","author":"Cardinal","year":"2015"},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0330","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1590\/1984-0462\/;2017;35;2;00001","article-title":"Clinical features and pattern of fractures at the time of diagnosis of osteogenesis imperfecta in children","volume":"35","author":"Brizola","year":"2017","journal-title":"Rev. Paul. Pediatr."},{"issue":"1","key":"10.1016\/j.bone.2019.04.011_bb0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BPO.0b013e318279c55d","article-title":"Fractures at diagnosis in infants and children with osteogenesis imperfecta","volume":"33","author":"Greeley","year":"2013","journal-title":"J. Pediatr. Orthop."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008200903108472","article-title":"RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta","volume":"51","author":"Bargman","year":"2010","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.bone.2019.04.011_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.matbio.2015.12.008","article-title":"Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta","volume":"52-54","author":"Berman","year":"2016","journal-title":"Matrix Biol."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0350","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.2770","article-title":"Strontium Ranelate reduces the fracture incidence in a growing mouse model of osteogenesis imperfecta","volume":"31","author":"Shi","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0355","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00223-002-2101-7","article-title":"The interaction between Sillence type and BMD in osteogenesis imperfecta","volume":"73","author":"Kok","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.04.011_bb0360","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0365","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"issue":"26","key":"10.1016\/j.bone.2019.04.011_bb0370","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","author":"Kusu","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2019.04.011_bb0375","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.04.011_bb0380","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2014.05.022","article-title":"Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta","volume":"66","author":"Albert","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.04.011_bb0385","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2013.12.020","article-title":"Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility","volume":"61","author":"Carriero","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.04.011_bb0390","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2019.04.011_bb0395","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bpj.2011.11.3999","article-title":"Structural and mechanical differences between collagen homo- and heterotrimers: relevance for the molecular origin of brittle bone disease","volume":"102","author":"Chang","year":"2012","journal-title":"Biophys. J."},{"issue":"6","key":"10.1016\/j.bone.2019.04.011_bb0400","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"van Bezooijen","year":"2009","journal-title":"J. Dent. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.04.011_bb0405","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.04.011_bb0410","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.matbio.2010.06.006","article-title":"Skeletal muscle weakness in osteogenesis imperfecta mice","volume":"29","author":"Gentry","year":"2010","journal-title":"Matrix Biol."},{"issue":"8","key":"10.1016\/j.bone.2019.04.011_bb0415","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11999-015-4268-z","article-title":"Are changes in composition in response to treatment of a mouse model of osteogenesis imperfecta sex-dependent?","volume":"473","author":"Boskey","year":"2015","journal-title":"Clin. Orthop. Relat. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219301474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219301474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:12:44Z","timestamp":1778940764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219301474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":83,"alternative-id":["S8756328219301474"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.04.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}